Conditions: Dermatomyositis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 5
Healthy volunteers: no

Brief summary:
This study is designed to evaluate the safety and efficacy of an oral medicine (called apremilast) for treating skin involvement in patients with the disease dermatomyositis.

Detailed description:

Arms:
arm 1: apremilast 20mg bid

Interventions: intervention 1: Apremilast
Intervention descriptions: intervention 1: Apremilast 20mg PO BID

Protocol document: